#METABOLOMICS WORKBENCH hormel101_20170711_150406 DATATRACK_ID:1119 STUDY_ID:ST000791 ANALYSIS_ID:AN001259 PROJECT_ID:PR000574
VERSION             	1
CREATED_ON             	July 12, 2017, 2:43 pm
#PROJECT
PR:PROJECT_TITLE                 	Mayo Pilot and Feasibility: Identifying metabolic adaptations characteristic of
PR:PROJECT_TITLE                 	multiple myeloma cells via mass spectrometry-based metabolite profiling
PR:PROJECT_SUMMARY               	Multiple myeloma (MM) is a clonal plasma cell malignancy that remains incurable
PR:PROJECT_SUMMARY               	in most afflicted patients. It can be preceded by an asymptomatic, premalignant
PR:PROJECT_SUMMARY               	stage known as smoldering multiple myeloma (SMM) that does not require therapy
PR:PROJECT_SUMMARY               	but has an increased life-long risk of progression to MM. However, one-third of
PR:PROJECT_SUMMARY               	SMM patients are “high risk” for imminent progression to MM within two years
PR:PROJECT_SUMMARY               	of diagnosis compared to the remainder of SMM patients who continue on an
PR:PROJECT_SUMMARY               	indolent asymptomatic course for several years. The diagnosis of MM cannot be
PR:PROJECT_SUMMARY               	made until they experience overt end-organ damage such as renal failure, lytic
PR:PROJECT_SUMMARY               	bone destruction, anemia and hypercalcemia. Currently, we lack sensitive
PR:PROJECT_SUMMARY               	biomarkers that can identify all SMM patients at high risk of progression to MM.
PR:PROJECT_SUMMARY               	Being able to identify high risk SMM patients could allow us to initiate
PR:PROJECT_SUMMARY               	systemic chemotherapy before they progress to MM. Cancer cells undergo distinct
PR:PROJECT_SUMMARY               	metabolic adaptations to meet the augmented cellular demand for energy and
PR:PROJECT_SUMMARY               	nutrients created by their increased rates of cellular proliferation. The
PR:PROJECT_SUMMARY               	presence of an altered cellular metabolism in clonal PCs from MM patients and
PR:PROJECT_SUMMARY               	its role as an essential factor in the progression of SMM to MM is unknown. We
PR:PROJECT_SUMMARY               	hypothesize that the clonal PCs in high risk SMM patients likely have an altered
PR:PROJECT_SUMMARY               	metabolic phenotype similar to those present in MM patients but different when
PR:PROJECT_SUMMARY               	compared to clonal PCs in the remainder of the SMM patients whose clinical
PR:PROJECT_SUMMARY               	course remains indolent. Thus, two specific aims are proposed in this study: Aim
PR:PROJECT_SUMMARY               	1 will verify if there are differences in the regulation of the metabolic
PR:PROJECT_SUMMARY               	pathways in clonal PCs from MM patients compared to normal PCs from healthy
PR:PROJECT_SUMMARY               	patients; Aim 2 will assess whether the clonal PCs from high risk SMM patients
PR:PROJECT_SUMMARY               	bear a distinct metabolic phenotype compared to clonal PCs from standard risk
PR:PROJECT_SUMMARY               	SMM patients.
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	Gonsalves
PR:FIRST_NAME                    	Wilson
PR:ADDRESS                       	200 First St. SW, Rochester, Minnesota, 55905, USA
PR:EMAIL                         	gonsalves.wilson@mayo.edu
PR:PHONE                         	507-266-0792
#STUDY
ST:STUDY_TITLE                   	Identifying metabolic adaptations characteristic of multiple myeloma cells via
ST:STUDY_TITLE                   	amino acids concentrations from bone marrow plasma
ST:STUDY_SUMMARY                 	Will be assessing the targeted amino acids concentrations of high risk versus
ST:STUDY_SUMMARY                 	low risk smoldering myeloma patients based on peripheral blood plasma and bone
ST:STUDY_SUMMARY                 	marrow plasma.
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	Gonsalves
ST:FIRST_NAME                    	Wilson
ST:ADDRESS                       	200 First St. SW, Rochester, Minnesota, 55905, USA
ST:EMAIL                         	gonsalves.wilson@mayo.edu
ST:PHONE                         	507-266-0792
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	ms6274-1	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-2	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-3	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-4	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-5	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-6	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-7	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-8	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-9	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-10	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-11	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-12	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-13	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-14	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-15	Grouping:Quick Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-16	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-17	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-18	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-19	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-20	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-21	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-22	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-23	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-24	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-25	Grouping:Slow Progress	sample type=bone marrow plasma; species=human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-26	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-27	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-28	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-29	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-30	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-31	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-32	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-33	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-34	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-35	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-36	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-37	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-38	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-39	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-40	Grouping:Quick Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-41	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-42	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-43	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-44	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-45	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-46	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-47	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-48	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-49	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
SUBJECT_SAMPLE_FACTORS           	-	ms6274-50	Grouping:Slow Progress	sample type=peripheral plasma; species=Human
#COLLECTION
CO:COLLECTION_SUMMARY            	"In order to analyze the metabolites of clonal PCs (intracellular) and BM plasma
CO:COLLECTION_SUMMARY            	(extracellular) separately, they have to be separated out from the BM samples.
CO:COLLECTION_SUMMARY            	Thus, upon acquiring the BM samples from patients they will be placed in
CO:COLLECTION_SUMMARY            	centrifuged at 2500 rpm for 10 minutes to separate out the plasma from the
CO:COLLECTION_SUMMARY            	cellular fraction. The separated BM plasma is then stored in separate vials and
CO:COLLECTION_SUMMARY            	snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for
CO:COLLECTION_SUMMARY            	further analysis. The leftover cellular component present as a pellet will be
CO:COLLECTION_SUMMARY            	washed and reconstituted with an equal volume of RPMI 1640 medium. Erythrocytes
CO:COLLECTION_SUMMARY            	are lysed using ammonium chloride lysing solution. After incubation on ice for 5
CO:COLLECTION_SUMMARY            	min, the cell suspension is diluted with RPMI medium. The cells are again
CO:COLLECTION_SUMMARY            	pelleted by centrifugation and then suspended in RoboSep buffer (250ml PBS, 2%
CO:COLLECTION_SUMMARY            	BSA, 1mM EDTA). The clonal CD138 positive PCs are purified using positive
CO:COLLECTION_SUMMARY            	selection by mixing the cells with a CD138 positive selection cocktail and
CO:COLLECTION_SUMMARY            	anti-CD138 magnetic-activated cell separation microbeads (ROBOSEP™ cell
CO:COLLECTION_SUMMARY            	separation system, StemCell Technologies Inc) in the automated RoboSep cell
CO:COLLECTION_SUMMARY            	separation system. The purified samples containing only CD138 positive cells are
CO:COLLECTION_SUMMARY            	re‐suspended and then centrifuged to form a cell pellet. The goal will be to
CO:COLLECTION_SUMMARY            	obtain at least 1-2 x 107 clonal PCs per sample. The cell pellet will be snap
CO:COLLECTION_SUMMARY            	frozen under liquid nitrogen for 20 seconds before storing at -80οC for further
CO:COLLECTION_SUMMARY            	analysis. Both the BM plasma samples as well as the clonal PCs pellet will be
CO:COLLECTION_SUMMARY            	provided to the metabolomics core for sample preparation for LC-MS analysis. For
CO:COLLECTION_SUMMARY            	Aim 2, we will be using stored BM samples from SMM patients that have already
CO:COLLECTION_SUMMARY            	had their BM plasma and clonal PCs separated from each other and stored at
CO:COLLECTION_SUMMARY            	-80οC. It is important to note that all these samples were collected and frozen
CO:COLLECTION_SUMMARY            	in a timely manner. Furthermore consistency in sample collection, storage and
CO:COLLECTION_SUMMARY            	processing is imperative for the optimal conduct of metabolomics-based
CO:COLLECTION_SUMMARY            	experiments. This ensures that all samples being analyzed and compared with each
CO:COLLECTION_SUMMARY            	other would have been manipulated similarly, limiting any handling biases. All
CO:COLLECTION_SUMMARY            	patient samples in the Predolin Foundation Biobank were collected and stored by
CO:COLLECTION_SUMMARY            	following a standardized operating procedure. BM samples were processed for BM
CO:COLLECTION_SUMMARY            	plasma separation and clonal PCs enrichment but were then immediately snap
CO:COLLECTION_SUMMARY            	frozen for storage at -80οC within approximately 3 hours of collection from the
CO:COLLECTION_SUMMARY            	patient. All samples were collected in patients who have been fasting for at
CO:COLLECTION_SUMMARY            	least 6 to 8 hours prior. To further ensure consistency in our analysis of this
CO:COLLECTION_SUMMARY            	study, we will only use samples that have never been thawed since initial
CO:COLLECTION_SUMMARY            	storage to preserve the stability of the metabolites originally present in the
CO:COLLECTION_SUMMARY            	samples."
#TREATMENT
TR:TREATMENT_SUMMARY             	We will use matched BM plasma and purified clonal marrow PCs from the BM samples
TR:TREATMENT_SUMMARY             	of SMM patients collected at the time of their diagnosis and stored within the
TR:TREATMENT_SUMMARY             	Mayo Clinic Predolin Foundation Biobank. We will select BM samples from patients
TR:TREATMENT_SUMMARY             	with SMM who progressed to MM within 2 years of their samples being collected
TR:TREATMENT_SUMMARY             	and stored; this will constitute the high risk SMM group. We will also select BM
TR:TREATMENT_SUMMARY             	samples from SMM patients who have not progressed to MM within at least 2 years
TR:TREATMENT_SUMMARY             	of follow up of their samples being collected and stored; this will constitute
TR:TREATMENT_SUMMARY             	the standard risk SMM group. The strength of this approach is that we will
TR:TREATMENT_SUMMARY             	utilize stored SMM samples from one of the most comprehensively characterized
TR:TREATMENT_SUMMARY             	monoclonal gammopathy biobanks available. Secondly, all samples will be obtained
TR:TREATMENT_SUMMARY             	from collection dates at least 2 years prior in order to ensure adequate
TR:TREATMENT_SUMMARY             	follow-up time to assess their current clinical status. This would avoid the
TR:TREATMENT_SUMMARY             	need to prospectively collect samples from SMM patients and clinically follow
TR:TREATMENT_SUMMARY             	them for a number of years before we are able to gauge who were clinically high
TR:TREATMENT_SUMMARY             	or standard risk for progression. There are over 700 SMM patients who have had
TR:TREATMENT_SUMMARY             	their BM samples collected and stored in the biobank from 1996 to 2013; more
TR:TREATMENT_SUMMARY             	than half these patients have progressed to MM.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	amino acids concentrations
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Waters Acquity BEH C18 (150 x 2.1mm, 1.7um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	Thermo Quantum Ultra
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	uM
MS_METABOLITE_DATA_START
Samples	ms6274-1	ms6274-2	ms6274-3	ms6274-4	ms6274-5	ms6274-6	ms6274-7	ms6274-8	ms6274-9	ms6274-10	ms6274-11	ms6274-12	ms6274-13	ms6274-14	ms6274-15	ms6274-16	ms6274-17	ms6274-18	ms6274-19	ms6274-20	ms6274-21	ms6274-22	ms6274-23	ms6274-24	ms6274-25	ms6274-26	ms6274-27	ms6274-28	ms6274-29	ms6274-30	ms6274-31	ms6274-32	ms6274-33	ms6274-34	ms6274-35	ms6274-36	ms6274-37	ms6274-38	ms6274-39	ms6274-40	ms6274-41	ms6274-42	ms6274-43	ms6274-44	ms6274-45	ms6274-46	ms6274-47	ms6274-48	ms6274-49	ms6274-50
Factors	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Quick Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress	Grouping:Slow Progress
Histidine	96.9	86.0	117.4	96.7	125.6	126.3	72.6	82.9	81.7	99.5	79.4	120.1	85.0	120.8	91.1	83.0	96.1	117.2	89.7	156.8	76.2	91.3	68.3	77.3	80.9	40.6	37.7	29.7	25.6	29.0	24.3	12.0	36.2	29.8	31.6	25.4	21.1	22.9	34.7	34.2	29.5	35.7	32.7	30.8	16.6	27.2	22.6	19.5	31.3	21.6
Hydroxyproline	8.4	10.1	12.0	10.1	8.0	5.9	10.4	5.9	7.6	8.7	19.8	8.2	4.7	6.3	4.6	7.1	4.6	28.3	9.1	10.1	4.2	4.9	12.5	7.4	3.0	11.0	10.2	8.7	5.1	5.0	6.5	6.6	4.3	6.2	11.4	16.0	4.1	3.6	7.7	6.6	4.9	6.5	4.4	8.6	25.4	7.5	5.3	10.8	13.3	4.7
1-Methylhistidine	17.4	18.4	9.0	5.9	1.5	2.6	8.0	13.7	19.7	8.3	1.8	1.5	2.3	26.4	5.1	21.1	0.0	48.5	11.7	0.4	14.8	11.6	1.3	17.5	0.0	6.6	4.8	10.1	23.2	3.4	17.2	2.6	6.9	15.6	4.9	5.6	1.8	0.8	7.4	7.5	4.4	5.2	4.6	12.6	37.6	20.5	0.0	2.1	4.3	3.9
3-Methylhistidine	5.3	4.1	14.0	4.9	3.8	6.0	5.4	3.9	4.5	5.8	5.4	5.0	2.1	16.1	6.3	4.0	5.1	24.7	3.6	9.3	4.2	3.5	1.9	7.5	1.2	13.7	8.3	7.4	8.8	8.4	10.0	8.0	6.2	7.0	4.4	5.7	8.2	4.6	4.3	5.0	4.9	4.0	6.3	8.1	35.6	7.6	6.0	15.7	10.5	4.7
Asparagine	28.1	27.1	30.0	22.6	43.4	31.7	23.5	32.8	37.1	27.6	17.2	28.3	29.3	9.1	24.6	28.6	26.2	39.5	35.0	41.2	29.7	10.3	11.6	15.3	28.2	20.9	2.5	3.0	1.3	0.6	0.6	1.1	43.7	30.8	23.0	0.7	0.6	2.4	2.4	6.2	1.2	10.8	1.0	9.1	1.4	18.8	1.2	1.1	0.6	16.7
Phosphoethanolamine	0.9	2.3	0.0	0.0	2.5	1.5	4.2	4.0	1.8	2.1	12.8	3.8	2.2	6.5	2.0	2.7	4.5	6.6	3.1	3.6	4.6	0.0	0.0	0.0	0.0	1.3	2.3	3.8	1.2	0.9	1.5	0.7	0.9	0.9	0.5	3.1	1.5	3.7	0.0	0.0	0.7	1.8	0.0	1.0	1.1	1.2	1.1	0.8	0.6	1.2
Arginine	42.4	46.9	59.9	31.7	45.0	51.3	29.4	35.3	50.0	50.3	12.3	47.4	54.7	34.9	40.8	58.4	63.6	39.5	32.6	58.9	31.6	30.2	17.5	25.4	43.2	73.1	60.5	71.5	73.7	64.9	85.6	23.7	48.2	54.5	65.2	35.5	44.3	55.5	99.1	95.7	74.4	43.4	70.9	46.0	22.1	43.7	41.8	66.4	67.8	23.4
Carnosine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Taurine	44.1	79.1	89.8	107.8	65.6	46.7	64.1	49.9	49.9	57.5	91.7	44.0	60.3	91.5	53.6	38.0	38.7	68.4	49.1	115.6	51.0	88.3	54.2	61.0	72.0	66.4	74.2	107.3	66.9	44.2	67.4	31.6	39.6	42.3	53.7	71.6	66.1	127.2	62.7	34.4	33.9	68.6	62.1	50.6	66.7	36.9	17.9	98.2	50.2	65.0
Anserine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Serine	76.8	68.3	74.2	65.7	60.4	35.1	53.7	56.9	45.7	58.7	47.9	59.8	72.9	52.1	51.0	63.9	55.4	63.2	58.7	73.4	68.9	45.2	120.5	54.2	50.7	105.1	114.0	99.8	118.8	73.2	95.7	97.4	102.9	102.5	109.4	144.0	129.3	92.4	127.3	154.5	108.4	103.1	196.7	89.6	77.5	98.0	60.3	92.6	84.6	83.5
Glutamine	402.0	445.7	419.7	282.3	507.9	403.7	364.5	423.4	404.6	504.7	13.4	484.7	409.1	239.9	456.2	381.5	452.2	529.7	385.7	503.7	339.9	216.1	44.0	149.7	335.9	383.9	37.7	44.2	7.2	0.0	0.0	3.7	612.7	400.1	303.6	0.0	17.2	16.9	24.3	239.3	148.5	134.5	32.6	7.9	0.0	1.4	49.9	0.0	0.7	142.1
Ethanolamine	6.6	14.1	23.6	42.0	15.6	7.8	13.0	9.5	9.1	10.0	9.9	8.4	10.3	7.9	6.8	8.1	7.7	11.3	9.7	7.4	8.3	16.7	12.2	16.7	16.4	4.9	8.5	5.1	7.2	5.1	5.4	6.9	7.6	6.5	6.2	4.2	5.9	5.2	12.5	5.8	5.8	7.6	11.5	6.4	5.6	4.6	8.7	4.7	6.5	4.7
Glycine	323.7	238.9	249.3	160.6	228.8	208.4	192.4	216.0	140.2	166.7	192.4	185.6	255.0	189.9	186.0	219.0	209.7	342.9	167.5	365.7	166.1	205.8	269.0	173.2	186.4	293.6	179.0	217.4	252.7	208.2	218.1	207.6	270.5	196.1	225.7	186.7	323.8	310.7	215.5	290.7	309.4	189.5	288.8	233.6	354.1	181.4	142.4	355.3	214.1	208.2
Aspartic Acid	3.8	11.7	14.1	19.7	7.4	7.2	8.2	6.1	5.0	6.4	12.9	5.3	5.3	24.6	6.2	7.4	7.7	11.5	6.7	7.6	6.1	12.2	8.1	10.4	10.0	27.7	28.9	37.0	44.3	9.1	8.6	25.8	11.8	18.7	22.5	3.9	25.3	31.0	40.4	62.2	43.3	45.9	53.8	24.6	29.9	18.9	24.4	38.0	30.3	21.6
Sarcosine	0.3	0.7	0.8	0.9	0.4	0.6	0.3	0.4	1.2	0.7	5.8	0.4	0.2	6.6	0.2	0.6	0.8	1.3	1.1	1.4	0.5	0.4	0.4	0.4	0.2	3.6	3.0	1.3	3.6	3.0	3.0	2.2	2.9	3.1	4.6	4.3	2.2	1.5	0.7	0.5	3.1	4.5	0.5	2.8	4.2	3.4	3.3	4.7	2.7	2.4
Citrulline	20.6	16.4	26.6	16.9	24.1	19.8	21.3	18.5	26.5	28.3	29.9	23.1	18.1	37.6	27.6	24.0	28.4	45.8	17.3	17.6	17.0	14.9	13.4	24.8	22.9	33.9	30.6	26.0	42.2	36.2	34.8	33.0	28.8	54.8	59.5	11.5	24.5	28.4	33.0	36.3	42.6	44.7	27.1	54.3	65.7	31.5	42.0	29.2	46.5	19.1
Glutamic Acid	28.9	72.5	123.1	198.6	69.4	58.2	82.9	60.1	32.0	50.6	433.9	43.7	32.0	200.1	36.4	39.9	74.3	65.1	41.3	75.5	39.8	153.3	288.4	236.8	128.3	226.2	511.5	474.6	564.5	570.8	519.2	477.3	130.1	238.9	482.9	607.3	473.2	572.3	556.6	386.2	470.1	541.3	573.3	681.3	425.2	464.8	468.6	538.7	524.8	291.5
beta-Alanine	1.1	1.3	2.1	3.5	2.2	1.2	2.9	1.4	1.9	0.8	2.4	1.6	0.6	1.7	1.6	2.8	1.6	3.9	3.5	0.9	0.9	1.1	0.5	2.7	1.1	2.5	3.8	4.6	3.0	2.1	1.5	2.5	2.5	2.2	1.3	3.9	1.4	2.2	2.4	1.6	2.7	3.0	1.8	4.5	4.2	6.6	0.5	1.6	2.8	0.9
Threonine	75.2	107.3	102.3	73.2	90.6	58.1	77.9	68.9	107.4	76.4	85.1	61.2	71.5	116.4	61.2	103.7	58.7	100.9	98.5	103.0	71.3	48.9	90.2	60.2	67.1	150.1	123.3	105.0	109.7	86.3	88.7	122.7	130.6	206.5	156.9	133.1	113.4	82.2	142.5	130.1	144.6	157.0	134.4	162.7	121.7	125.7	89.4	109.2	105.9	101.9
Alanine	248.6	176.2	366.4	440.5	277.7	313.3	387.8	213.8	352.0	271.5	279.7	225.8	219.0	280.7	202.8	242.8	340.5	258.7	197.5	455.3	188.2	195.1	168.4	241.8	248.8	507.5	420.9	222.6	299.9	335.6	310.4	493.8	307.9	296.4	439.2	472.6	305.0	244.6	217.4	311.6	330.0	381.8	198.4	415.0	315.5	239.9	300.6	477.5	512.1	396.2
gamma-Amino-N-butyric-acid	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.2	0.3	0.5	0.7	0.2	0.2	0.1	0.1	0.3	0.1	0.4	0.5	0.2	0.1	0.3	0.4	0.3	1.4	0.2	0.3	0.1	0.6	0.1	0.1
alpha-Aminoadipic-acid	0.3	0.4	0.7	1.7	0.4	0.7	0.9	0.7	1.4	0.6	1.0	0.4	0.3	2.4	0.4	0.4	0.5	0.9	0.9	0.6	0.4	0.8	0.1	1.2	0.3	0.7	1.1	0.7	0.4	0.8	1.1	0.8	0.6	1.0	0.6	1.9	0.2	0.4	0.4	0.7	0.3	0.7	0.3	0.9	0.3	1.6	0.4	0.6	0.7	0.7
beta-Aminoisobutyric-acid	0.8	1.5	1.3	0.7	0.9	0.8	0.9	1.0	1.2	1.0	1.2	0.9	1.3	3.2	4.8	3.8	0.8	5.8	0.9	1.1	0.6	1.2	0.0	1.1	0.5	1.4	1.1	1.6	1.0	1.2	0.6	0.9	1.2	2.1	0.8	0.4	1.5	2.1	0.8	0.9	4.3	0.8	0.8	0.9	4.4	1.1	0.2	1.5	2.0	0.7
Proline	83.8	188.4	172.6	206.1	195.7	188.2	135.6	125.9	244.8	141.9	237.5	145.4	102.1	163.9	111.5	148.0	165.2	158.5	207.9	190.5	96.3	87.0	87.3	108.2	140.3	236.3	196.2	117.8	137.4	187.2	105.4	193.8	154.4	183.5	229.0	310.3	107.1	109.4	156.8	169.8	163.4	177.6	119.0	255.1	171.6	186.2	260.1	179.2	219.5	147.2
Hydroxylysine 1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Hydroxylysine 2	0.3	0.5	0.2	0.4	0.2	0.4	0.8	0.2	0.6	0.4	0.9	0.3	0.2	0.4	0.2	0.2	0.4	0.5	0.3	0.5	0.3	0.2	0.3	0.2	0.2	0.4	0.5	0.3	0.2	0.4	0.4	0.9	0.2	1.0	0.5	1.3	0.2	0.4	0.4	0.5	0.2	0.4	0.3	0.4	1.1	0.3	0.5	0.8	0.3	0.4
alpha-Amino-N-butyric-acid	24.5	26.4	13.5	19.3	14.5	20.3	17.4	16.1	19.4	13.8	23.2	16.0	22.5	35.1	11.4	19.0	11.8	21.1	18.9	14.1	17.6	20.1	11.8	15.7	7.3	18.9	23.9	26.2	19.0	17.1	17.2	19.3	18.7	27.2	13.5	22.2	27.6	9.2	22.0	17.6	19.1	26.3	27.3	16.4	18.9	18.6	22.6	18.2	19.4	20.8
Ornithine	34.0	45.6	73.4	77.4	41.0	37.5	44.2	51.0	71.0	57.3	102.9	40.2	36.1	75.8	48.7	30.1	59.2	86.2	47.4	51.8	48.1	40.3	57.8	76.0	48.7	123.3	109.4	49.8	62.0	83.6	70.7	77.7	66.8	90.4	145.8	90.6	103.0	55.4	38.2	42.1	47.2	115.2	67.8	74.9	126.8	82.2	78.6	82.1	76.8	78.9
Cystathionine 1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.6	0.0	0.0	0.4	0.0	0.0	0.0	1.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.3	0.3	0.1	0.1	0.2	0.1	0.3	0.2	0.8	0.5	0.4	0.1	0.2	0.2	0.2	0.2	0.5	0.1	0.6	0.9	0.3	1.2	0.2	0.1	0.7
Cystathionine 2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Lysine	105.7	115.4	152.1	141.6	117.7	148.1	128.5	126.9	139.6	145.7	148.5	119.9	109.9	207.9	117.8	110.7	128.6	147.6	121.2	183.9	118.4	143.9	92.8	142.4	117.6	168.6	171.6	181.4	160.2	175.4	209.9	149.0	176.1	193.9	208.6	173.2	177.9	132.5	178.9	186.3	157.1	189.4	191.7	167.1	148.0	154.4	102.7	222.7	166.4	139.2
Cystine	19.5	53.8	19.1	2.3	37.7	36.6	61.7	41.1	50.9	60.6	1.1	25.5	35.8	1.1	45.9	27.4	50.9	93.4	34.9	51.6	39.6	0.5	0.0	0.7	0.9	12.1	0.2	0.4	1.6	0.8	0.3	0.4	0.7	0.9	0.4	0.7	0.2	0.7	0.6	0.8	0.6	0.5	0.4	0.6	2.8	0.4	0.6	0.2	0.2	0.1
Tyrosine	41.9	30.8	36.7	38.8	47.8	42.9	52.6	34.8	54.9	42.7	46.6	32.7	35.3	42.4	36.3	32.4	51.9	29.0	47.0	35.1	34.5	35.6	37.0	43.1	32.4	49.8	52.5	44.5	58.1	67.0	62.4	79.8	63.7	84.9	79.9	61.2	57.7	51.0	75.8	85.2	50.5	93.6	63.2	74.0	29.6	68.2	168.0	39.5	58.7	60.7
Methionine	17.4	15.3	20.8	16.7	17.0	16.5	17.5	14.1	18.5	16.2	6.8	17.5	14.5	14.7	15.3	17.5	16.5	16.9	16.7	18.8	15.7	13.0	11.2	17.1	13.5	7.8	3.6	2.0	1.4	0.0	1.2	0.0	23.3	23.6	19.6	6.6	0.0	3.8	2.7	6.1	8.4	16.7	3.1	12.2	0.0	0.5	5.9	0.6	0.0	8.2
Valine	131.3	155.3	155.4	209.3	171.1	147.8	197.9	131.5	207.4	145.2	237.3	130.3	134.3	247.4	150.1	149.5	172.7	144.0	188.0	181.0	148.1	160.4	114.2	168.2	133.8	198.3	252.6	145.5	160.1	181.5	235.7	242.6	185.5	281.3	223.4	291.8	176.6	163.3	202.6	220.6	158.6	265.5	206.1	308.6	128.8	244.1	142.6	215.8	240.1	166.3
Isoleucine	35.8	45.5	44.2	55.1	38.0	38.3	50.6	31.4	61.5	37.3	46.4	51.9	38.8	60.5	40.9	39.2	45.1	63.4	53.6	39.4	38.6	43.3	27.8	47.5	32.3	70.5	67.2	48.9	52.7	58.3	58.0	59.6	50.0	72.4	61.5	81.9	61.4	61.9	66.8	56.6	56.3	99.2	50.5	98.5	45.5	80.6	37.3	56.1	71.0	42.9
allo-Isoleucine	1.2	1.6	0.8	2.3	1.5	1.3	1.9	1.4	1.1	1.2	2.4	2.0	1.3	1.9	1.2	1.9	1.5	0.9	1.1	2.1	0.9	1.3	1.0	1.5	0.9	0.9	3.0	1.8	2.5	1.8	2.4	2.2	1.8	1.6	1.5	4.7	2.8	1.8	2.1	1.2	2.0	3.6	1.2	2.2	2.9	1.8	1.1	3.3	1.5	2.4
Homocystine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Leucine	66.5	70.3	63.0	89.4	85.0	63.4	78.9	56.4	80.1	73.0	102.0	74.1	75.7	112.5	83.2	59.3	76.6	82.3	95.2	86.1	72.6	80.5	45.5	89.3	67.8	107.9	123.8	83.6	90.5	98.9	114.8	103.1	92.2	125.0	111.8	148.4	120.6	70.5	114.5	109.6	86.6	154.7	106.4	172.2	61.0	135.5	64.7	114.8	128.2	101.8
Phenylalanine	42.2	33.9	40.3	40.5	39.0	37.2	43.3	29.4	48.1	40.1	45.4	39.8	35.3	47.4	43.9	29.1	40.0	40.3	44.3	37.8	40.6	37.8	24.1	40.0	29.6	61.2	53.8	45.1	57.3	53.5	58.5	69.2	51.5	71.6	64.5	63.5	57.3	42.0	61.5	82.0	44.5	69.9	75.7	79.4	42.9	67.8	72.0	43.8	67.2	79.3
Tryptophan	22.5	17.9	19.0	26.4	32.3	31.0	26.4	17.9	23.8	25.0	28.0	17.8	18.5	22.4	22.0	18.5	23.0	17.2	23.5	28.5	25.2	17.6	20.8	22.5	23.0	29.4	42.0	35.0	54.5	44.5	51.6	46.5	36.1	46.1	52.3	41.0	33.0	39.6	59.9	37.7	38.8	56.3	55.0	66.8	22.1	48.0	55.2	36.1	56.8	49.3
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
Histidine
Hydroxyproline
1-Methylhistidine
3-Methylhistidine
Asparagine
Phosphoethanolamine
Arginine
Carnosine
Taurine
Anserine
Serine
Glutamine
Ethanolamine
Glycine
Aspartic Acid
Sarcosine
Citrulline
Glutamic Acid
beta-Alanine
Threonine
Alanine
gamma-Amino-N-butyric-acid
alpha-Aminoadipic-acid
beta-Aminoisobutyric-acid
Proline
Hydroxylysine 1
Hydroxylysine 2
alpha-Amino-N-butyric-acid
Ornithine
Cystathionine 1
Cystathionine 2
Lysine
Cystine
Tyrosine
Methionine
Valine
Isoleucine
allo-Isoleucine
Homocystine
Leucine
Phenylalanine
Tryptophan
METABOLITES_END
#END